Results overview: Found 5 records in 0.02 seconds.
Articles, 5 records found
Articles 5 records found  
1.
10 p, 1.8 MB Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis / Reich, Kristian (University Medical Center Hamburg-Eppendorf) ; Conrad, Curdin (University Hospital Lausanne CHUV) ; Kristensen, Lars Erik (Lund University) ; Smith, Saxon D. (The University of Sydney) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Rich, Phoebe (Oregon Dermatology and Research Center) ; Sapin, Christophe (Eli Lilly and Company) ; Holzkaemper, Thorsten (Eli Lilly and Company) ; Koppelhus, Uffe (Eli Lilly and Company) ; Schuster, Christopher (Medical University of Vienna) ; Universitat Autònoma de Barcelona
Nail psoriasis (NP) is common and of high importance in patients with psoriasis. Complete resolution of NP at week 24‒26 is an unambiguous nail outcome accessible for indirect treatment comparison of biologics. [...]
2022 - 10.1080/09546634.2021.1892024
Journal of Dermatological Treatment, Vol. 33 Núm. 3 (2022) , p. 1652-1660  
2.
14 p, 695.4 KB Comparative effectiveness of biologics in clinical practice : week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO) / Pinter, Andreas (University Hospital of Frankfurt (Alemanya)) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Schäkel, Knut (Heidelberg University Hospital (Alemanya)) ; Reich, Adam (Institute of Medical Sciences. Medical College of Rzeszow University) ; Zaheri, Shirin (Imperial College Healthcare NHS Trust) ; Costanzo, Antonio (Humanitas Research Hospital Pieve Emanuele (Milà, Itàlia)) ; Tsai, Tsen-Fang (National Taiwan University Hospital and National Taiwan University College of Medicine) ; Smith, Saxon Donald (Australian National University,College of Health and Medicine) ; Lynde, Charles W. (University of Toronto) ; Brnabic, Alan (Eli Lilly and Company) ; Reed, Catherine L. (Eli Lilly and Company) ; Hill, Julie (Eli Lilly and Company) ; Schuster, Christopher F. (Medical University of Vienna) ; Riedl, Elisabeth (Medical University of Vienna) ; Paul, Carle (Paul Sabatier University and Larrey Hospital (Toulose, França)) ; Universitat Autònoma de Barcelona
Background: Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice. [...]
2022 - 10.1111/jdv.18376
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 11 (november 2022) , p. 2087-2100  
3.
11 p, 464.0 KB Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis / de Bruin-Weller, Marjolein (University Medical Center Utrecht) ; Serra-Baldrich, E (Institut d'Investigació Biomèdica Sant Pau) ; Barbarot, Sebastien (Department of Dermatology. Nantes Université. CHU Nantes. INRAE) ; Grond, Susanne (Eli Lilly and Company) ; Schuster, Christopher (Eli Lilly and Company) ; Petto, Helmut (Eli Lilly and Company) ; Capron, Jean-Philippe (Eli Lilly and Company) ; Raibouaa, Afaf (Eli Lilly and Company) ; Werfel, Thomas (Division of Immunodermatology and Allergy Research. Department of Dermatology and Allergy. Hannover Medical School) ; Universitat Autònoma de Barcelona
Introduction: Indirect treatment comparison was used to compare approved doses of baricitinib and dupilumab for treating adult patients with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. [...]
2022 - 10.1007/s13555-022-00734-w
Dermatology and Therapy, Vol. 12 Núm. 6 (june 2022) , p. 1481-1491  
4.
18 p, 2.0 MB Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis : Results at Week 12 from the PSoHO Study in a Real-World Setting / Lynde, Charles (Lynde Institute for Dermatology (Markham, Canadà)) ; Riedl, Elisabeth (Medical University of Vienna. Department of Dermatology) ; Maul, Julia-Tatjana (University of Zurich. Faculty of Medicine) ; Torres, Tiago (Centro Hospitalar Universitário do Porto) ; Pinter, Andreas (University Hospital Frankfurt. Department of Dermatology, Venereology and Allergology) ; Fabbrocini, Gabrielle (University of Naples Federico II. Section of Dermatology, Department of Clinical Medicine and Surgery) ; Daniele, Flavia (Medica Dermatologa en Swiss Medical Group (Buenos Aires, Argentina)) ; Brnabic, Alan (Eli Lilly and Company) ; Reed, Catherine (Eli Lilly and Company) ; Wilhelm, Stefan (Eli Lilly and Company) ; Holzkämper, Thorsten (Eli Lilly and Company) ; Schuster, Christopher (Eli Lilly and Company) ; Puig Sanz, Lluís (Institut de Recerca Sant Pau) ; Universitat Autònoma de Barcelona
In routine clinical care, important treatment outcomes among patients with moderate-to-severe plaque psoriasis (PsO) have been shown to vary according to patient demographics and disease characteristics. [...]
2023 - 10.1007/s12325-022-02379-9
Advances in Therapy, Vol. 40 (march 2023) , p. 869-886  
5.
3 p, 147.0 KB Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab / Brunner, Patrik M. (Medical University of Vienna) ; Conrad, Curdin (Lausanne University Hospital) ; Vender, Ronald (Dermatrials Research Inc) ; Grond, Susanne (Eli Lilly and Company, Indianapolis) ; Schuster, Christopher F. (Eli Lilly and Company, Indianapolis) ; Patel, Hanna (Eli Lilly and Company, Indianapolis) ; Xu, Wen (Eli Lilly and Company, Indianapolis) ; Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
2021 - 10.1111/bjd.20527
British journal of dermatology, Vol. 185 (august 2021) , p. 865-867  

See also: similar author names
2 Schuster, Christopher F.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.